Quote of the Day

“While it is too early to publish results, we can confirm significant cost savings for each patient who transitions to home-based infusion or treatment at a Walgreens infusion suite. For example, on average, we expect an infliximab [i.e., Remicade] patient to save approximately $20,000 per year through a site-of-care transition, although some patients can save much more. It is not uncommon for the site-of-care savings to exceed $100,000 per year for patients receiving immune globulin, eculizumab [i.e., Soliris] or other drugs that treat rare diseases. — Mike Ellis, corporate VP of specialty pharmacy and infusion at Walgreens, told AIS’s Specialty Pharmacy News.